New hope for controlling debilitating nosebleeds in rare disease
NCT ID NCT04976036
Summary
This study is testing whether a drug called nintedanib can reduce the frequency and severity of nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT), a rare genetic disorder. About 48 adult participants with moderate to severe nosebleeds will be randomly assigned to take either nintedanib capsules or a placebo (inactive pill) twice daily for 16 weeks. The main goal is to see if the drug significantly reduces the total time spent bleeding from the nose compared to the placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TELANGIECTASIA, HEREDITARY HEMORRHAGIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Angiology Department, Lausanne University Hospital
COMPLETEDLausanne, Canton of Vaud, 1011, Switzerland
-
Clermont-Ferrand university hospital
RECRUITINGClermont-Ferrand, 63000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lyon University Hospital, Dpt of genetics
RECRUITINGBron, 69677, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.